Funding for this research was provided by:
Canadian Institutes of Health Research (143340, Doctoral award)
Fondation Brain Canada (Brain Canada)
Heart and Stroke Foundation of Canada
Canada Research Chairs
Received: 4 October 2021
Accepted: 19 January 2022
First Online: 8 February 2022
Change Date: 11 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13063-022-06134-x
: The study protocol has received ethical approval from the Research Ethics Board at the University of British Columbia (H19-02005: version A012, July 21, 2021; H20-03983: version A002, November 18, 2021), Vancouver, British Columbia, Canada; the Health Research Ethics Board at the University of Manitoba (HS23659 [H2020:074]: version 10, April 23, 2021), Winnipeg, Manitoba; the Conjoint Health Research Ethics Board at the University of Calgary (REB20-0294: version REN 1, June 22, 2021), Calgary, Alberta; Western Health Sciences Research Ethics Board (WHSREB ID 116362: version 3, April 20, 2021); Research Ethics Board at Sunnybrook Health Sciences Centre (Project ID 2115: version 4, January 18, 2021), Toronto, Ontario; the Research Ethics Board at the University Health Network (Project ID 19-6138: version 2, May 4, 2021), Toronto, Ontario; and the Research Ethics Board at Nova Scotia Health (REB #1025328: version 5, April 23, 2021), Halifax Nova Scotia.Operational approval has also been granted by the Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada; Alberta Health Services, Edmonton, Alberta, Canada; and Lawson Health Research Institute, London, Ontario, Canada. All participants will provide signed informed consent to participate in the RCT and qualitative study.
: Not applicable.
: Dr. Menon has a vested interest in commercializing the technology and may benefit financially from its potential commercialization through BioInteractive Technologies. The other authors declare that they have no competing interests.